DEA Drew a Real Line on Kratom. Whether It Holds Isn't Decided Yet.

Morgan Godvin knows opioid withdrawal from the inside — she’s written about her own history with it in unsparing detail. So when she tapered herself off nine months of daily kratom use, she braced for the same thing. It didn’t come. She took her last dose on a Saturday and went hiking the next day, no detox required. That gap — between what kratom does in someone’s body and what scheduling language implies it does — is the terrain DEA is fighting over right now, with a comment period that just closed on your behalf whether you filed one or not.

Here’s where things stand, because coverage has been muddy. On July 1, DEA said it intended to temporarily place 7-hydroxymitragynine (7-OH) and three related compounds into Schedule I, heroin’s legal category, via two notices in the Federal Register on July 6. Only one track has landed: on August 25, DEA finalized a temporary order scheduling three synthetic, lab-derived compounds — mitragynine pseudoindoxyl, MGM-15, and MGM-16 — effective through August 26, 2028. HHS and FDA say these show up almost nowhere but overdose toxicology: 56 cases tied to one of them, 48 fatal.

The DEA has not scheduled kratom, and it has not finalized 7-OH scheduling either — both remain proposals, not law, as of this week.

The 7-OH piece — the one that touches what most people mean by “kratom” — is that unfinalized proposal. DEA’s line sits at 0.05% 7-OH by weight, roughly 1 milligram a dose, meant to separate ordinary leaf and tea (where 7-OH forms naturally at trace levels) from the synthesized, concentrated gas-station shots that are the real clinical problem. HHS and FDA say explicitly this targets “deliberately manufactured and concentrated” products, not the botanical plant. The comment window closed September 10 — extended by only 15 of the 60 days advocates requested, after the earlier round had already drawn 32,000-plus comments. That volume tells you how many people — pain patients, people tapering off opioids on their own, retailers — have a stake in exactly where DEA draws that decimal point.

The threshold logic is sound on paper. Whether it stays narrow depends on lab-testing mechanics DEA hasn’t fully locked down: its own language leaves “enforcement discretion” over whether trace, incidental amounts of the now-Schedule-I synthetics in an ordinary product get treated as botanical kratom or as a felony. The American Kratom Association didn’t trust that discretion — it sued DEA in late August, not to overturn the order but to force a court to confirm it can’t sweep up leaf testing positive for trace, naturally formed amounts. That’s the gap between a legal product on shelves and a raid.

A federal rule won’t touch the part underneath it: your state already has its own answer. Roughly a dozen states ban kratom outright; more than a dozen others regulate it under Kratom Consumer Protection Act frameworks with their own alkaloid caps and age limits — a patchwork that existed before DEA said a word and will still exist after. If you use kratom, what’s legal on your kitchen counter has always been a state question first. A finalized federal threshold adds a floor. It doesn’t erase the map you’re already living inside.

Naloxone access hasn’t moved. If kratom or 7-OH has been part of how you manage opioid use, that safety net is still there regardless of what DEA finalizes next.